Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
+44 1300 500008
ISSN: 2376-0419
+44 1300 500008
Dhruv Patel, Dharna Patel and Chetna Patel Veer Narmad
Veer Narmad South Gujarat University, India
Posters-Accepted Abstracts: J Pharma Care Health Sys
Rituximab is a chimeric monoclonal antibody to CD 20 antigen. It is commonly used in treatment of non-Hodgkin��?s lymphoma & rheumatoid arthritis. Rituximab is also under investigation for the treatment of other conditions including chronic lymphocytic leukemia, multiple sclerosis, ANA associated vasculitis & SLE including lupus nephritis. Rituximab has been reported to be effective in patients, including children & infants, with idiopathic thrombocytopenic purpura refractory to standard treatment. Some of the most common side effects of rituximab are infusion related symptoms such as fever, chills, rigors & flushing. Pulmonary reaction has been reported including reversible interstitial pneumonia & interstitial fibrosis. Gastrointestinal disturbances may occur, which includes abdominal pain, bowel obstruction & perforation. Severe reactions like tumor lysis syndrome, acute renal failure, respiratory failure, reactivation of hepatitis B virus & progressive multifocal leuco-encephalopathy may occur. Late onset neutropenia has been reported in patients receiving rituximab. Here we report a case of thrombocytopenia that occurs after rituximab infusion in idiopathic thrombocytopenic purpura.
Dhruv Patel has completed his MBBS from Veer Narmad South Gujarat University at Government Medical College, Surat. He is pursuing Post-Graduate course in clinical pharmacology. He has attended many national and state level conferences.
Email: drdhruv1986@gmail.com